Mediark Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 7

Mediark General Information

Description

Developer of a biopharmaceutical delivery platform designed to cater biomaterials and pharmaceutical businesses. The company's platform provides porous source materials and customized biopharmaceutical particles by designing metal combinations optimized for immune activity cell regeneration, enabling chemical and biotechnology businesses to use in them for applications like adsorption, catalysis, drug delivery, and pharmaceutical development.

Contact Information

Website
www.mediark.kr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 541, Building 019, Startup Incubation Center
  • 1 Chungdae-ro, Seowon-gu, Gaesin-dong, Chungbuk National University
  • Cheongju, Chungcheongbuk
  • South Korea
+82
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • Room 541, Building 019, Startup Incubation Center
  • 1 Chungdae-ro, Seowon-gu, Gaesin-dong, Chungbuk National University
  • Cheongju, Chungcheongbuk
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mediark Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 07-May-2025 Completed Generating Revenue
4. Accelerator/Incubator 07-Aug-2024 Completed Generating Revenue
3. Seed Round 10-Feb-2023 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Mediark’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Mediark Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mediark Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
JB Investment (Seoul) Corporate Venture Capital Minority
JNP Global Accelerator/Incubator Minority
Tech Incubator Program for Startup Accelerator/Incubator
Center for Creative Economy and Innovation Accelerator/Incubator Minority
Reventures Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Mediark FAQs

  • When was Mediark founded?

    Mediark was founded in 2022.

  • Where is Mediark headquartered?

    Mediark is headquartered in Cheongju, South Korea.

  • What is the size of Mediark?

    Mediark has 10 total employees.

  • What industry is Mediark in?

    Mediark’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Mediark a private or public company?

    Mediark is a Private company.

  • What is Mediark’s current revenue?

    The current revenue for Mediark is .

  • Who are Mediark’s investors?

    JB Investment (Seoul), JNP Global, Tech Incubator Program for Startup, Center for Creative Economy and Innovation, and Reventures are 5 of 7 investors who have invested in Mediark.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process